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ABSTRACT
Application of microemulsion for 
enhancing topical skin absorption 
of 20(S)-protopanaxadiol 
and oral absorption of rebamipide
Ki Taek Kim
Department of Pharmaceutical Sciences
The Graduate School
Seoul National University
20(S)-protopanaxadiol (20S-PPD) is an aglycosylated metabolite of 
ginsenosides such as compound K and ginsenoside Rb1, and possesses a potent 
skin anti-aging activity. However, due to its low aqueous solubility and large 
molecular size, a suitable formulation strategy is required in order to enhance skin 
deposition of 20S-PPD by improving its solubility and skin permeability. 
Rebamipide (RBP) is a potent anti-ulcer and anti-oxidative agent, which belongs to
biopharmaceutics classification system (BCS) class IV with a poor oral 
bioavailability of less than 10%. Thus, enhancing the systemic exposure of RBP 
may increase its pharmacological activities after oral administration. The objective 
of the study was to develop microemulsion (ME)-based systems for the topical skin 
delivery of 20S-PPD and for the oral delivery of RBP. 20S-PPD-loaded ME and
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ME-based hydrogel (MEH) formulations were prepared and evaluated in terms of 
their particle size distribution, morphology, maximum loading capacity, viscosity, 
and pH value. Then, the in vitro and in vivo deposition or permeation profiles of
20S-PPD in the selected MEH formulation were studied using hairless mouse skin 
model and artificial skin model, Strat-M® membrane. A Carbopol-based MEH 
system of 20S-PPD was successfully prepared with a mean droplet size of 110 nm 
and polydispersity index of 0.436. The formulation was stable at least for 56 days, 
and its viscosity was high enough for its topical skin application. It significantly 
enhanced the in vitro and in vivo skin deposition of 20S-PPD with no influence on 
its systemic absorption in hairless mice. Notably, it was found that the rank of the 
tested formulaions in the order of decreasing deposition of 20S-PPD in in vitro 
Strat-M® membrane and in vitro/in vivo hairless mouse skin was same. For RBP-
loaded ME, characterization study (i.e. maximum loading capacity, particle size 
distribution, and morphology), in vitro drug release study, in vivo pharmacokinetic 
study, and intestinal toxicity study were performed. Capmul MCM EP and Solutol 
HS15-based ME system of RBP had spherical nano-sized droplets with 
polydispersity index of 0.265 and neutral zeta potential. Moreover, the prepared 
ME significantly enhanced the dissolution and oral bioavailability of RBP with no 
discernible intestinal toxicity. Taken together, the ME-based systems developed in 
this study could serve as a potentially effective topical skin and oral delivery 
system for enhancing the absorption of poorly soluble compounds including 20S-
PPD and RBP.
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Background
1.1. Fick’s diffusion law
In general, passive diffusion process is considered as main mechanism of 
absorption into the skin and gastro-intestinal (GI) membrane [1,2]. In this reason, 
the molecules which have low aqueous solubility would show limited absorption
through the skin and GI membrane [3]. Absorption into the skin and GI membrane 
via passive diffusion mechanism can be described by Fick’s laws [1,4]. 
J is the flux (g/cm2·sec) which means the rate of diffusion flows through unit area. 
M is the amount (g) of diffusant that penetrated the membrane after time t (sec). S 
is the area (cm2) of membrane applied. D is the diffusion coefficient (cm2/sec) of 
the diffusant. C1 is the concentration (g/mL) of diffusant in the membrane at the 
donor side. C2 is the concentration of diffusant in the membrane at the receptor side, 
and h is the thickness (cm) of membrane.
    
K is the partition coefficient of diffusant into membrane. Cd is the concentration of 
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diffusant in donor solution. Cr is the concentration of diffusant in receptor solution. 
The rate of diffusion (dM/dt) can be expressed as follows:
P is the permeability coefficient (cm/s). Assuming the sink condition at the receptor 
side, Cr is nearby almost 0. Therefore, the cumulative amount diffused (M) through
membrane can be expressed as follows (Equation 6 and 7):
As shown in the equation 6 or 7, M is proportional to P, S, and t. Also, as Cd 
increases, M will be increased. In oral delivery, the receptor side may be blood 
capillary which can be considered as sink condition. Thus, the absorption into GI 
membrane will be increased as the concentration of diffusant in its formulation 
after the oral administration (Cd). In topical skin delivery, the deposition into the 
epidermis and dermis of skin may be accumulated over time, which it may be non-
sink condition. Nonetheless, the absorption and deposition into the skin will be 
increased as the concentration of diffusant in its formulation applied to the skin 
(Cd) increases by the rule of Fick’s laws [4]. Therefore, solubilization of 
hydrophobic molecules can be the main approach for their enhanced absorption via 
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passive diffusion into the skin and GI membrane. 
1.2. Microemulsion (ME)-based systems 
Recent studies have suggested that modified formulations of poorly water-
soluble agents such as solid dispersion, inclusion complexation, liposomes, and 
nanoparticles could enhance their solubility, thereby increasing bioavailability or 
absorption [5]. Among these strategies, microemulsion (ME)-based systems have 
been widely used for clinical and commercial products to overcome their own 
solubility problem [5]. 
ME is composed of oil, water, and surfactant mixture (Smix) phase, which 
is isotropic, transparent and thermodynamically stable colloidal system with 
droplet sizes ranging from 10 to 200 nm [6,7]. MEs are clearly different from 
coarse emulsions that are cloudy in appearance (1 to 20 μm) and less stable than 
MEs [7]. In contrast to emulsions, MEs must need much more surfactant and, 
unlike emulsions, also co-surfactant which enable low interfacial tension in ME 
droplets [6]. The oil components of ME have usually been used with triglycerides 
(i.e. olive oil, soybean oil, and medium chain triglycerides), fatty acids (i.e. oleic 
acid and linoleic acid) or fatty acid esters (i.e. isopropyl myristate and isopropyl 
palmitate) [8]. In aqueous phase of ME, distilled water (DW) or buffer solution has 
been used. Natural surfactant including lecithin, non-ionic surfactant such as 
polysorbates (Tween 20 and Tween 80), sorbitane monooleate (Span 80), labrasol, 
and poloxamer or ionic surfactant including sodium lauryl sulfate and cetyl-
trimethyl ammonium bromide has widely been used as surfactant phase of ME. The 
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co-surfactants of ME have usually been used with short- and medium-chain 
alcohols (i.e. ethanol and 1-butanol) or their derivatives (i.e. propylene glycol and
transcutol) [8]. Among those phase in ME systems, hydrophobic molecules can be 
solubilized in the oil phase and/or adsorbed into the oil-water interface of ME, 
which allows higher loading capacity of the ME formulation, enhancing the driving 
force of their penetration through the membrane of skin or GI membrane [8,9]. By 
the ratio of water, oil and Smix phase, the different structures of ME-based systems 
can be formed [8,10]. As the water phase in ME increase, the structure would be 
near to micelle. On the other hand, as the Smix phase in ME increase, the structure 
would be presented bicontinuously or lamellarly, not spherically. Among the 
different MEs, oil in water (o/w) ME which can solubilize hydrophobic molecules 
can be formed when the water phase exists more than the oil phase and the 
proportion of Smix phase is medium [10]. Although there are continuous diffusional 
processes and collisions at the interfaces of ME droplets, the equilibrium size and 
shape of the droplets are maintained [10]. 
To apply ME-based systems transdermally, topically, or orally, the 
acceptability of surfactants must be considered [8,10]. Because large amounts of a 
surfactant and a co-surfactant are required for ME systems, it might be cause 
intolerance like irritation, sensitization, and erythema [8]. Those side-effects can be 
minimized by a careful selection of the ME components. Among them, generally, 
non-ionic surfactants have been reported to have minimal toxicity compared with 
ionic surfactants, therefore, being more suitable for the use in ME-based systems
[8,10]. Representatively, Tween 20 and Tween 80 have been widely used and 
accepted for transdermal and oral administration [8]. Labrasol (caprylocaproyl 
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macrogol-8 glycerides) and Solutol HS 15 (polyethylene glycol (15)-hydroxy-
stearate), also have been investigated as surfactant in o/w ME [8]. Those 
surfactants were reported as biodegradable and only mildly irritating agents. To 
overcome the safety issues, the ME systems could be formulated without co-
surfactant. However, these ME systems are more easily destabilized during storage
[10]. Therefore, adequate amount of co-surfactant are needed for formation of 
stable ME with relatively low toxicity.  
1.3. Microemulsion (ME) systems for topical skin and oral 
delivery
The ME-based systems has been widely applied for improvement of 
topical skin transport into and across skin layer, because some ingredients of ME 
formulation such as surfactants can serve as permeation enhancers to overcome 
barrier functions of skin [11,12]. ME applied topically was shown to enhance
accumulation of quercetin as an anti-oxidant at the target site in the skin without 
increasing its systemic absorption [13]. In topical delivery of triptolide as anti-
inflammatory agent, isopropyl myristate (oil phase) and Tween 80 (surfactant 
phase) based ME was developed and enhanced the skin deposition of triptolide [14]. 
Also, o/w MEs delivered ascorbyl palmitate to the skin significantly higher than its 
solution, thereby enhancing its efficacy as anti-oxidant [15]. In several researches, 
it was demonstrated that a combination of ME and phospholipids or 
phosphatidylcholines could improve topical skin delivery of drugs via the enhanced 
flexibility of ME droplets with skin layers [16,17]. However, the topical skin
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application of ME in the clinical or commercial fields has been often hindered due 
to its low viscosity. Thus, ME-based hydrogels (MEHs) have attracted as an 
alternative topical skin delivery system to solve the problem of low viscosity of 
MEs [6,18]. In general, MEH with an appropriate viscosity and good 
biocompatibility can prolong the retention time on the skin and reduce the risk of 
skin irritation after its topical application [18,19]. Moreover, the mean droplet size, 
surface charge, and morphology of ME entrapped in the gel networks might be not 
significantly changed during gelation process compared to that of MEs [6,9]. MEs 
incorporated into carbopol gels were prepared and evaluated for topical delivery of 
terbinafine hydrochloride [20]. In another study, ME-based hydrogel for topical 
administration of fluconazole was developed [21]. Gelatin-containing ME-based 
gel using Tweem 85 and isopropyl myristate as surfactant was also investigated for 
skin delivery of sodium salicylate [22]. Soy bean phosphatidylcholine (lecithin)-
containing ME-based gel has been investigated for skin delivery and skin irritation 
test was performed in humans, which showed a very low irricacy potential [23]. 
The ME-based systems offer several merits over conventional oral 
formulation, including enhanced absorption, improved pharmacological potency 
and negligible drug toxicity [24]. Unlike emlusion, MEs can be stable in aqueous 
media and even, in the gastro-intestinal fluids without emulsification by bile salts. 
Due to its nano-sized droplets and permeation-enhancing effect by surfactants, 
consequently, this systems leads to improved oral absorption of drugs [24]. Among 
ME-based systems, o/w MEs can significantly improve the oral bioavailability of 
hydrophobic drugs [10]. Curcumin, well-known as poorly water-soluble compound, 
was solubilized in o/w MEs, thereby its dissolution and in vivo oral absorption 
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being improved [25]. Furthermore, these o/w MEs can enhance the oral absorption
of BCS class IV drugs which have a low solubility and a low permeability (i.e. 
docetaxel and paclitaxel) [10]. ME systems containing docetaxel was prepared and 
investigated for its solubilization effect and enhancement of in vitro dissolution and 
in vivo oral bioavailability [26]. Also, the oral absorption of paclitaxel was 
significantly enhanced by ME systems [27]. The developed MEs increased both the 
dissolution and permeability of paclitaxel. To overcome the stability of MEs and its 
large volume, self-micro emulsifying drug delivery system (SMEDDS) has been 
developed. SMEDDS is mixture of oils, surfactants, and co-surfactants which are 
self-emulsified in the gastro-intestinal fluid after the oral administration [24]. It 
also can improve the oral absorption of BCS class IV drugs. The drug release and 
oral bioavailability of simvastatin was improved via SMEDDS containing Carpryol 
90, Cremophor EL, and Transcutol [28]. Neoral®, a SMEDDS of cyclosporin 
which contained oil solution of drug and surfactants, has been introduced to replace 
conventional crude emulsion of cyclosporine, Sandimmune® [29].
In summary, MEs as drug delivery systems improved the absorption of 
hydrophobic compounds into the skin or oral, which was attributed by their 
capacity of solubilization and permeation-enhancing effect.
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Part I. Microemulsion-based hydrogels for 
enhancing epidermal/dermal deposition of 
topically administrated 20(S)-protopanaxadiol: 
in vitro and in vivo evaluation
1. Introduction
Among a number of active compounds in ginseng, ginsenosides are 
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known to be mainly responsible for diverse pharmacological effects of ginseng [30]. 
Among the various effect, ginsenoside F1 and Rb1 were reported to have anti-
melanogenic activity in human skin and B16 cells, respectively [31,32]. More 
recently, a compound K-rich fraction prepared from ginseng was reported to have 
anti-photoaging activity by modulating several signaling pathways in α-MSH-
treated B16F10 cells and UVB-irradiated NIH3T3 fibroblasts [33]. However, those 
studies were conducted by using classical formulations such as solutions and 
creams for the topical dermal application of ginsenosides. Considering a limited 
solubility and membrane permeability of ginsenosides mentioned above [34,35], 
further studies on suitable topical delivery systems are warranted to develop more 
effective cosmeceutical preparations containing ginsenosides.
20(S)-protopanaxadiol (20S-PPD, Fig. 1) is an agly-cosylated metabolite 
of ginsenosides such as compound K, Rb1, Rb3, Rg3, and Rh2 [36]. It possesses 
various pharmacological activities such as cardio-protective, antitumor, anti-
inflammatory and antidepressant effects [36,37]. Notably, a recent study 
demonstrated that 20S-PPD presented markedly higher anti-wrinkle and skin-
whitening effects compared with compound K and Rb1 in immortalized human 
keratinocytes and 3D-cultured human skin equivalent models, by the suppression 
of matrix metalloproteinases which are capable of degrading collagen and elastin in 
the epidermis and dermis of skin [38]. However, there also have been no studies 
about delivery systems on the topical skin delivery of 20S-PPD up to date. 
Moreover, due to the low aqueous solubility of 20S-PPD (< 50 ng/mL), as well as 
its relatively large molecular size (460.7 Da), its permeation through the stratum 
corneum and deposition in the epidermis and dermis parts of skin would be 
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restrictive based on the Fick’s laws of diffusion [1,3]. Therefore, a suitable 
formulation strategy to improve the solubility and skin permeability of 20S-PPD is 
essential for its epidermal and dermal deposition enhancement. Moreover, to our 
best knowledge, there have been no studies which reported the topical application 
of 20S-PPD with nano-sized delivery systems including MEs and MEHs which 
have been considered to be appropriate for topical skin delivery. For these reasons, 
both MEs and MEHs were studied as delivery systems for the enhanced topical 
delivery of 20S-PPD in the present study. 
Due to a limited availability of obtaining human skin and its high 
variability in lipid and protein compositions depending on bodyweights, genders, 
ages, diets, etc., hairless mouse skin has been widely regarded as a useful 
alternative to human skin on development of topical skin and transdermal 
formulations [39]. Previous studies have reported a good correlation of skin 
permeation profiles between human and hairless mouse skin due to the similarity of 
skin structures and lipid or protein compositions between them [40]. Also, in recent 
researches on topical skin delivery including cosmetic agents, the substitution for 
using animals in evaluation of skin absorption has been magnified. To substitute for 
animal skins for the evaluation of skin deposition or permeation, several artificial 
membranes were developed and have been studied [41,42]. Among them, Strat-M®
membrane (Merck Millipore Co., Darmstadt, Germany), one of the commercially 
available, skin-mimic artificial membranes, has been recently introduced and 
widely used as non-animal based model [41]. Strat-M® membrane is composed of 
two layers of polyether sulfone which could represent the stratum corneum of skin 
and one layer of polyolefin which is more porous and diffusive, thereby could 
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represent the dermis of skin [42]. Due to these similarities, the membrane has been 
reported to have good-correlation in skin permeation profiles with human and 
animal skins [41,42]. However, to our best knowledge, little information is 
available regarding the correlation of skin deposition profiles between Strat-M 
membrane and animal skins. Therefore, in the present study, prepared ME and 
MEH formulations containing 20S-PPD were evaluated on its deposition by using
hairless mouse skin and also, using Strat-M® membrane.
Finally, the objective of the present study is to investigate the feasibility 
of applying pharmaceutical drug delivery technology to the topical delivery of 20S-
PPD by using MEs and MEHs. The 20S-PPD-loaded ME and MEH formulations 
were prepared by the construction of pseudo ternary phase diagram and 
characterized in vitro in terms of loading capacity, particle-size distribution, 
morphology, surface charge, viscosity, and long-term stability. Then, the in vitro
and in vivo skin deposition properties of the prepared ME and MEH formulations 
were studied using hairless mice and Strat-M® membrane, a skin-mimic artificial 
membrane. Additionally, the correlation of skin deposition profiles of 20S-PPD
between hairless mouse skin and Strat-M® membrane was investigated.
2. Materials and Methods
2.1. Materials
12
20(S)-protopanaxadiol (20S-PPD) (purity ≥ 98.0%) was purchased from Xian Plant 
Bio-Engineering Co., Ltd. (Shaanxi, China). Capmul MCM EP was gifted as a 
sample from ABITEC Co. (Columbus, OH, USA). Labrafac CC, Lauroglycol CC, 
labrasol (PEG-8 caprylic/capric glycerides) and Transcutol HP were gifted as 
samples from Gattefossé Co. (Saint Priest, Cedex, France). Tween 20, isopropyl 
myristate, Limonene, polyethylene glycol 400 (PEG400), sodium lauryl sulfate 
(SLS), soybean phosphatidyl choline (soy PC), xanthan gum, triethanolamine, and 
ketoprofen were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 
USA). Poloxamer 407 was obtained from BASF Co. (Ludwigshafen, Germany). 
Carbopol 941 was obtained from The Lubrizol Co. (Wickliffe, OH, USA). 
Phosphate buffered saline (PBS) was purchased from Lonza, Ltd. (Basel, 
Switzerland). HPLC grade methanol and acetonitrile were purchased from Thermo 
Fisher Scientific Co. (Pittsburgh, PA, USA). All other reagents were of analytical 
grade. 
2.2. Animal
For in vitro and in vivo evaluation, male hairless mice (5 weeks age, 
20‒25 g) were used and obtained from Orient Bio Inc. (Sungnam, Korea). They 
were bred on sawdust and five mice were in each cage. They had free access to 
water and food before the studies. Room illumination was on an automatic cycle of 
12 hr light/darkness, and room temperature was maintained at 25 ± 2°C. They were 
acclimatized to the presented conditions for at least one week prior to the 
experiments. Experimental protocols for the animals (Approval number: SNU-
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111007-4-2) used in this study were reviewed by the Animal Care and Use 
Committee of the College of Pharmacy, Seoul National University and were in 
accordance with the National Institutes of Health’s Guide for the Care and Use of 
Laboratory Animals (National Institutes of Health Publication Number 85-23, 
revised 1985).
2.3. Solubility study
The equilibrium solubility of 20S-PPD in various vehicles was determined 
by adding excess amount of them into 1 mL of each vehicle. The mixtures 
containing 20S-PPD were allowed to approach an equilibrium state in a vortex 
shaker (Vortex-Genie 2; Scientific Industries, Inc., Bohemia, NY, USA) with 50 
rpm at 25°C for 72 hr. The samples were centrifuged at 16,000 x g for 5 min and 
the supernatant was filtrated with 0.20 μm syringe filter to remove the excess 
amount of 20S-PPD. Finally, the concentration of 20S-PPD in the filtrated solution 
was quantified by LC-MS/MS after appropriate dilution with methanol.
2.4. Construction of pseudo-ternary phase diagrams
Based on the solubility test of 20S-PPD (Table 1), Capmul MCM EP was 
selected as an oil phase, and Labrasol and Tween 20 were selected as a surfactant 
mixture (Smix) phase for 20S-PPD-loaded ME formulations. The pseudo-ternary 
phase diagram studies were performed to find a clear and transparent ME 
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formulations. The surfactant and co-surfactant were mixed at different ratios to 
form the surfactant mixture (Smix). Afterwards, the oil phase and the Smix were 
mixed, where the ratios of oil to Smix were varied as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 
2:8, and 1:9 (w/w). Then, the water phase (distilled water, DW) was added drop-
wise to each oil and Smix mixture at room temperature with stirring to allow 
equilibration. After equilibrium, the mixtures were visually checked for 
transparency. The points from clear to turbid state were presented on the diagrams.
2.5. Preparation of 20S-PPD-loaded ME and MEH formulations
From the clear region of pseudo-ternary phase diagrams, three ME 
formulations (P1‒P3) were selected for further evaluations (Table 2). For the 
preparation of MEs of 0.1% (w/w) 20S-PPD, exact amount of 20S-PPD was first 
added into Capmul MCM EP and vortex-mixed to dissolve 20S-PPD. Labrasol and 
Tween 20 mixtures were subsequently added to the 20S-PPD oil solution under 
gentle stirring at room temperature. Then, DW was added dropwise into the above 
mixture at the same condition. In order to investigate the synergic effect of co-
surfactants (i.e., Transcutol HP and Soy PC), they were added into the Smix, after 
which 20S-PPD in Capmul MCM EP and DW were added as described above (P4 
and P5, Table 2).
For the preparation of MEH, different hydrophilic polymers were used. 
An appropriate amount of hydrophilic polymers such as xanthan gum or poloxamer 
407 was added in the 20S-PPD-loaded ME and swelled overnight under magnetic 
stirring. After sonication for 10 min, the semisolid hydrogel was obtained. The final 
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concentration of xanthan gum and poloxamer 407 in each 20S-PPD-loaded MEH 
was 1.0% and 15.0% (w/w), respectively. For carbopol hydrogel, carbopol 941 was 
dispersed in the 20S-PPD-loaed ME and swelled overnight under magnetic stirring. 
Then, appropriated amount of triethanolamine (TEA) was added to neutralize the 
pH value until a semisolid hydrogel was obtained. The final concentration of 
carbopol 941 in 20S-PPD-loaded MEH was 1.0% (w/w). Selection of appropriate 
MEH for topical skin delivery among the various MEH formulations as mentioned 
above was performed by the observation of their visual appearance and 
determination of their viscosity.
2.6. Characterization of 20S-PPD-loaded ME and MEH
formulations
2.6.1. Particle size and zeta potential
The mean particle size, polydispersity index, intensity distribution of 
particle size, and zeta potential of 20S-PPD-loaded MEs were measured in 
triplicate by an electrophoretic light-scattering (ELS) spectrophotometer (ELS 
8000, Otsuka Electronics Co. Ltd., Tokyo, Japan). The prepared MEs were 
transferred to a quartz cuvette before the measurement. All measurements were 
performed at 25°C in triplicate. 
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2.6.2. TEM
The particle morphologies of 20S-PPD-loaded ME and MEH
formulations were observed by an energy-filtering transmission electron 
microscopy (TEM) (LIBRA 120, Carl Zeiss, Germany) at 80 kV. The samples were 
placed on a carbon-coated copper grid and negatively stained by 2% 
phosphotungstic acid followed by drying at room temperature before the operations.
2.6.3. pH
The pH value of 20S-PPD-loaded ME and MEH formulations was
evaluated by using a pH meter (OrionTM 3-Star Benchtop; Thermo Fisher 
Scientific Co.) at 25°C in triplicate after calibration with standard pH buffer 
solutions at the pH range of 4.0 to 10.0.
2.6.4. Viscosity
The viscosity of 20S-PPD-loaded ME and MEH formulations was 
evaluated using rotational viscosity measurement device coupled with concentric 
cylinder (LV1) at 25°C (Brookfield viscometer LVDVE; Brookfield Engineering 
Laboratories, Inc., Middleboro, MA, USA).
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2.6.5. Maximum loading capacity
To confirm the maximum 20S-PPD-loading capacity of ME and MEH 
formulations, excess 20S-PPD was added into the mixture of oil and Smix, after 
which the 20S-PPD-loaded MEs or MEH were prepared as the same method before. 
Then, excess 20S-PPD which was not included into the droplets of ME was
removed by centrifugation for 5.0 min at 16,000 x g. The supernatant was injected 
into LC-MS/MS for analysis of 20S-PPD after adequate dilution with methanol.
2.7. In vitro skin deposition study: hairless mouse skin and Strat-
M® membrane
Evaluation of in vitro deposition of 20S-PPD into hairless mouse skin 
was carried out by using Keshary-Chien diffusion cells at 32°C, which have 1.77 
cm2 of the surface area for diffusion. After sacrificing the hairless mice by cervical 
dislocation, the dorsal skin was cut to appropriated size and the subcutaneous fat 
was removed. Then, they were fixed between the donor and receptor cells, laying 
the stratum corneum toward the donor cells. The receptor cells were filled with 
PBS containing 1.0 w/v% SLS (13.0 mL). Afterwards, various 20S-PPD loaded 
MEs (P1 to P5) were applied into the donor cell and sealed with parafilm to avoid 
evaporation of samples. The skin was removed from the diffusion cells at 6 hr after 
applying samples and washed out with methanol. In order to determine the amount 
of 20S-PPD in stratum corneum, tape stripping method was used [39]. Cellophane 
adhesive tape (CuDerm corporation, Dallas, TX, USA) was applied three times on 
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the stratum corneum of the skin and the tapes of each time samples were separately 
collected into the 2.0 mL tube. The skin samples after removing the stratum 
corneum (i.e., epidermis and dermis) were chopped and collected into a mortar. 
The chopped samples were ground to powder using a pestle after adding liquid 
nitrogen. The skin powders were collected by Cellophane adhesive tape, and were 
transferred into the 2.0 mL tube. For extraction of 20S-PPD from the tapes, 
methanol (1.5 mL) was added and the tube was shaken for 3 hr, followed by 
centrifugation for 5.0 min at 16000 g. 
Evaluation of in vitro deposition of 20S-PPD into Strat-M® membrane 
was carried out by using the same diffusion cell. Strat-M® membrane which has a 
2.5 cm of diameter was fixed between the donor and receptor cells, laying the shiny 
side toward the donor cells. The receptor cells were filled with the same media as 
described above. Then, 20S-PPD in various vehicles (0.1%, w/w), i.e., MEs (P1 to 
P5), MEH (P5-H), suspension (DW and propylene glycol mixture; 9:1 w/w), and 
oil (Capmul MCM EP) solution, was applied into the donor cell and sealed with 
parafilm to avoid evaporation of samples. The Strat-M® membranes were removed 
from the diffusion cells at 3 hr after applying samples and washed out with 
methanol. Then, they were put into the 2.0 mL tube and added with the mixture of 
acetone and methanol (70:30 v/v%, 1.5 mL). For extraction of 20S-PPD from the 
Strat-M® membrane, the tube was shaken for 3 hr, followed by centrifugation for 
5.0 min at 16000 g. Then, an 1.0 mL aliquot of the supernatant was evaporated by a 
gentle nitrogen gas stream at 30°C and reconstituted with 0.5 mL of methanol. 
Finally, the amount of 20S-PPD in the stratum corneum and epidermis/dermis of 
hairless mouse skin at 6 hr and in Strat-M® membrane at 3 hr was analyzed using
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LC-MS/MS.
2.8. In vivo skin deposition study
Evaluation of in vivo skin deposition and permeation of 20S-PPD was 
carried out using a male hairless mouse as animal model. The mouse was slightly 
anesthetized with ether before the experiment and fixed laying the dorsal part 
upward. For applying suspension (DW and propylene glycol mixture; 9:1 w/w) and 
oil (Capmul MCM EP) solution, a specially designed cylinder-type chamber which 
has a diffusion area of 0.79 cm2 was put on the dorsal skin of mice and fixed with 
surgical glue (Vet bond®, 3M Co., St. Paul, MN, USA). After recovering from 
anesthesia, suspension or oil solution containing 0.1 % (w/w) of 20S-PPD was 
applied into the chamber for topical administration of 20S-PPD. Also, 20S-PPD
loaded MEH (P5-H) was applied on the same area of dorsal part by hand-rubbing. 
All formulation was administrated on the skin at a dose of 25 mg/kg. Before the 
sacrificing at 3, 6, and 12 hr, about 300 μL aliquot of blood sample was collected 
for evaluation of permeated 20S-PPD through the skin. Plasma samples were 
obtained by centrifugation for 5.0 min at 16000 g and stored at ‒20°C until LC-
MS/MS analysis. After blood sampling from the hairless mice, they were sacrificed 
by cervical dislocation. Then, the skin samples were pretreated as described in the 
in vitro skin deposition study to determine the deposited 20S-PPD into the skin by 
using LC-MS/MS.
20
2.9. Stability study 
The stability of 20S-PPD in various formulations at room temperature and 
40°C for 7, 14, 28, and 56 days was evaluated by comparing 20S-PPD content and 
change of particle size distribution. Briefly, oil solution, 20S-PPD loaded MEs (P1 
and P5) and MEH (P5-H) containing 0.1 % (w/w) of 20S-PPD were prepared and 
stored on the above conditions. At 0 (initial state), 7, 14, 28, and 56 days, mean 
particle size distribution of the samples was measured by the ELS 
spectrophotometer. For the determination of 20S-PPD content, the samples were 
centrifuged for 5.0 min at 16000 g, and then the supernatant was injected into LC-
MS/MS after adequate dilution with methanol.
2.10. LC-MS/MS analysis of 20S-PPD
The amount of 20S-PPD was determined by LC-MS/MS analysis as 
described previously [37]. The samples were injected into an Agilent LC-MS/MS 
system (Santa Clara, CA, USA) equipped with an Agilent Technologies 1260 
Infinity HPLC system and Agilent Technologies 6430 Triple Quad LC-MS system. 
The samples were injected through Hypersil BDS C18 column (50 mm×4.6 mm, 5 
µm; Thermo Fisher Scientific Co.). The mobile phase was 93% acetonitrile and 7% 
water containing 0.2% formic acid (v/v). The flow rate was 0.37 mL/min. 
Determination of 20S-20S-PPD was conducted in the multiple reaction monitoring 
mode with positive electrospray ionization (ESI). The gas temperature, gas flow, 
nebulizer pressure, and capillary voltage were 120°C, 9 L/min, 25 psi, and 6000 V, 
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respectively. The m/z value of precursor to product ion, fragment voltage, collision 
energy, and cell accelerator voltage for 20S-PPD were 461.4 to 425.5, 111 V, 4 eV, 
and 1 V, respectively. The analytical data were processed using the MassHunter 
Workstation Software Quantitative Analysis (vB.05.00; Agilent Technologies). 
The retention time of 20S-PPD was 1.09 min. The calibration standard samples 
were prepared by serial dilution with methanol, thereby yielding final 
concentration range of 2.0–1000 ng/mL. The response of detector was linear in the 
concentration range and the mean correlation coefficient (r2) for the calibration 
curve was over 0.999. The signal to noise ratio on the lower limit of quantification 
(LLOQ = 2.0 ng/mL) was higher than 5.0 and there was no interference from any 
other substances.
Plasma samples containing 20S-PPD were allowed to thaw at room 
temperature for analysis. A 100 µL aliquot of each sample was deproteinized with a 
1 mL aliquot of methanol containing 500 ng/mL ketoprofen as an internal standard 
(IS). After vortex-mixing for 5 min, followed by centrifugation at 16000 g for 5 
min, a 900 µL aliquot of the supernatant was transferred and evaporated by 
nitrogen gas at 40°C. Then, the film was reconstituted with a 100 µL aliquot of 
methanol. After vortex-mixing for 5 min, followed by centrifugation at 16000 g for 
5 min, the supernatant was injected into an Agilent LC-MS/MS system with the 
same column and MS/MS conditions. The mobile phase was 88% acetonitrile and 
12% water containing 0.2% formic acid (v/v). The flow rate was 0.40 mL/min. The 
m/z value of precursor to product ion, fragment voltage, collision energy, and cell 
accelerator voltage for 20S-PPD were the same as above. Those parameter for IS 
were 255.1 to 209.1, 110 V, 11 eV, 1 V, respectively. The retention time of 20S-
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PPD and IS was 1.17 and 0.51 min, respectively. The calibration standard samples 
were prepared by spiking working standard into the blank plasma, thereby yielding 
final concentration range of 2.0–1000 ng/mL. The response of detector was linear 
in the concentration range and the mean correlation coefficient (r2) for the 
calibration curve was over 0.999. The signal to noise ratio at the LLOQ (2.0 
ng/mL) was higher than 5.0.
2.11. Statistical analysis
All experiments in this study were performed at least three times, and the 
data are presented as mean ± standard deviation (SD). Statistical analyses were 
carried out using the two-tailed t-test or analysis of variance (ANOVA) with post-
hoc test (IBM SPSS Statistics software, version 21.0; IBM Corp, Armonk, NY, 
USA), and p < 0.05 was considered significantly different.
3. Results
3.1. Preparation of 20S-PPD-loaded ME and MEH formulations
Due to a low aqueous solubility of 20S-PPD in DW (36.8 ng/mL), 
various oils and surfactants were tested to select suitable vehicles for 20S-PPD. 
The rank of the tested compounds in the order of decreasing solubility of 20S-PPD
was as follows: Capmul MCM EP > Lauroglycol CC > Labrafac CC as oils; 
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Labrasol > Tween 20 > isopropyl myristate > limonene > PEG 400 as surfactants 
(Table 1). The pseudo-ternary phase diagrams consisting of water (DW), oil 
(Capmul MCM EP), and Smix are shown in Fig. 2. The Smix was the mixture of 
Labrasol and Tween 20 at three different ratios (1:1, 2:1, and 3:1, w/w). As shown 
in Fig. 2, the formation of clear and transparent ME was observed in constructing 
the pseudo-ternary phase diagrams with different Smix ratios. Three ME 
formulations were selected within the clear and transparent area of MEs prepared 
with the three different Smix ratios, i.e. P1, P2, and P3 (Table 2). Additionally,
Transcutol HP and soy PC were employed as co-surfactants in the ME formulations 
P4 and P5 (Table 2). Then, MEH formulations were prepared by the addition of 
gelling agents, such as xanthan gum, Poloxamer 407, or Carbopol 941, into P5.
3.2. Characterization of 20S-PPD-loaded ME and MEH 
formulations
The compositions of 20S-PPD-loaded ME formulations are listed in 
Table 2. Physicochemical properties including droplet size, polydispersity index, 
zeta potential of 20S-PPD-loaded MEs are presented in Table 3. The mean droplet
sizes of the prepared ME formulations (P1 to P3) ranged from 69.1 nm to 99.6 nm,
and P1 had the smallest particle size. When Transcutol HP and soy PC were added 
as co-surfactants in P1, the mean droplet size slightly (not significantly) increased 
up to 106 and 110 nm in P4 and P5, respectively. Surface charge of droplets was 
observed to near neutral in all the 20S-PPD-loaded ME formulations tested. 
Particle size distributions and TEM images of P1 and P5 showed that spherical and 
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nano-sized particles with a narrow-to-moderate size distribution were observed in 
20S-PPD-loaded MEs (Fig. 3).
MEH formulations were prepared by the addition of xanthan gum, 
Poloxamer 407, or Carbopol 941, into F5. When adding xanthan gum, a turbid and 
unclear formulation was observed. The rank of the viscosity of MEHs was as 
follows: Carbopol-based MEH (29400 mPa∙s) > xanthan gum-based MEH (8420 
mPa∙s) > Poloxamer-based MEH (657 mPa∙s). This result was consistent with the 
fluidity of MEHs observed in a horizontal position. Only Carbopol-based MEH 
was not flew down in a horizontal position. As shown in Fig. 3, it was confirmed 
by TEM picture that spherical droplets derived from P5 were located in the 
Carbopol gel (P5-H), and their droplet sizes looked similar to those of P5. The pH, 
viscosity, and maximum loading capacity values of the ME and MEH formulations 
are listed in Table 3. The pH value of P5-H (6.91) was close to neutral than those of 
other MEs (5.33 to 5.55). Besides, the viscosity of P5-H (29400 mPa∙s) was much 
higher than in other MEs (9.33 to 11.2 mPa∙s). There were no significant 
differences in maximum loading capacity among all the ME and MEH 
formulations tested, ranging from 3.56 to 3.94 mg/mL.
3.3. In vitro deposition of 20S-PPD in hairless mouse skin and 
Strat-M® membrane
Fig. 4 presents in vitro deposition of 20S-PPD at 6 hr in hairless mouse 
skin and at 3 hr in Strat-M® membrane after the topical application of P1, P2, and
P3. The deposited amount of 20S-PPD at 6 hr in epidermis/dermis of hairless 
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mouse skin was the highest in P1 (p < 0.01), while there was no significant 
difference on the deposition of 20S-PPD in the SC among the three ME 
formulations tested. Moreover, the 20S-PPD deposition at 3 hr in Strat-M®
membrane was higher in P1 than in P3 (p < 0.05). Fig. 5 shows the effect of co-
surfactants (Transcutol HP and soy PC) added in the ME formulation P1. Notably, 
the deposited amounts of 20S-PPD at 6 hr in the epidermis/dermis of hairless 
mouse skin were significantly higher in P4 and P5 than in P1 (p < 0.05), while
there was no significant difference on the deposition of 20S-PPD in the SC among 
the three ME formulations tested. Moreover, the 20S-PPD deposition at 3 hr in 
Strat-M® membrane was the highest in P5 (p < 0.01). Fig. 6 presents in vitro
deposition of 20S-PPD at 3 hr in Strat-M® membrane after the topical application 
of suspension, oil solution, and P5-H formulations. The deposited amount of 20S-
PPD was the highest in P5-H (p < 0.001), followed by oil solution and suspension
group.
3.4. In vivo skin deposition of 20S-PPD after topical application
Figs. 7 and 8 present the in vivo skin deposition profiles and plasma 
concentration of 20S-PPD, respectively at 3, 6, and 12 hr after the topical 
administration of suspension, oil solution, and P5-H formulations in hairless mice. 
In vivo skin deposition and plasma concentration of 20S-PPD tended to increase
over time in all the three formulations tested. The deposited amounts of 20S-PPD
in the SC at 3 and 6 hr and in the epidermis/dermis at 3, 6, and 12 hr were 
significantly higher in P5-H than in the two control formulations (p < 0.01; Fig. 7).
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However, there were no significant differences in the plasma concentrations of 
20S-PPD permeated at 6 and 12 hr among all the formulations tested.
3.5. Stability of 20S-PPD-loaded ME and MEH formulations
Stability of 20S-PPD in oil solution, P1, P5, and P5-H at room 
temperature and 40°C for 56 days was evaluated in terms of phase 
separation/aggregation, particle size distribution, and drug content (Fig. 10 and
Table 4). As a result, no aggregates were observed in the oil solution, P5, and P5-H 
formulations and their transparency also maintained through 56 days. However, the 
aggregates were observed in P1 at both temperatures on the 14th, 28th, and 56th 
day after preparation. Correspondently, these aggregates over 1.0 μm of particle 
size were observed on the particle size distribution of P1 and those portions in P1 
droplets increased through 56 days (Fig. 10). Moreover, the 20S-PPD contents of 
oil solution, P5 and P5-H remained nearly to 100% at both temperatures for 56 
days, while those of P1 were significantly reduced to 67.1% and 68.5% at room 
temperature and 40°C, respectively (Table 4).
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4. Discussion
The present study provided novel data on the development of ME or 
MEH formulations for the topical delivery of 20S-PPD in order to enhance its
absorption into the skin. To prepare ME systems for 20S-PPD, Capmul MCM EP 
was selected as an oil phase due to its higher ability to solubilize 20S-PPD as 
compared to the other oils tested (Table 1). Labrasol and Tween 20 were selected as 
constituents of Smix phase, due to their higher ability to solubilize 20S-PPD as 
compared to the other surfactants tested (Table 1). The selected surfactants with 
high hydrophilic-lipophilic balance (HLB) values, i.e. 14.0 for Labrasol and 16.7 
for Tween 20, are generally considered as emulsifiers suitable for the formation of 
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oil-in-water MEs [8]. In the pseudo-ternary phase diagram shown in Fig. 2, the 
three ME formulations (P1‒P3) with different Labrasol-to-Tween20 ratios were 
selected based on the principle of high water portion and low Smix portion within 
the transparent ME region [43]. Additionally, Transcutol HP (HLB = 4.2) and soy 
PC (HLB = 4.5) were employed as co-surfactants in the ME formulations F4 and 
F5 (Table 2) [44]. The combinations of high-HLB surfactants (i.e. Labrasol and 
Tween 20) and these low to medium-HLB co-surfactants are known to facilitate the 
formation of a stable ME [8,45]. Moreover, soy PC can increase the flexibility of 
oil-water interface, thereby enhancing physical stability of ME system [46,47]. The 
maximum loading capacity of 20S-PPD in all the ME formulations tested were 
above 3 mg/mL, which was markedly higher in comparison with the aqueous 
solubility of 20S-PPD in DW (36.8 ng/mL, Table 1). Based on this maximum 
loading capacity, the loading content of 20S-PPD in the ME formulations was set 
as 0.1% (w/w) for further studies in order to prevent aggregation and precipitation 
in ME system.
To prepare the MEH system, hydrophilic polymers such as xanthan gum, 
Poloxamer 407, and Carbopol 941 were employed as gelling agents in this study. 
However, the addition of xanthan gum to the ME formulations resulted in an 
instantaneous aggregate formation and considerably increased turbidity, probably 
due to an increase in oil-water interfacial tension caused by xanthan gum [48]. 
Moreover, the viscosities of poloxamer 407-based MEH formulations (657 mPa∙s 
at room temperature and 2840 mPa∙s at 32°C) were much lower than 20000 mPa∙s 
that is generally considered suitable for topical dermal application [6,49]. Carbopol 
has been widely regarded as an useful component of drug delivery gel systems for 
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dermal, ocular, buccal, nasal, and rectal applications [50]. Due to the rheological 
properties of Carbopol gels such as remarkable temperature stability, long 
relaxation time, and low thixotropy, they have been considered as appropriate 
delivery systems for topical delivery systems requiring prolonged drug residence 
time with enhanced skin retention [51]. In our present study, the prepared MEH 
formulation containing 1.0% (w/w) Carbopol 941 and 2.0% (w/w) triethanolamine 
(P5-H) was transparent in appearance and exhibited an appropriate viscosity 
(29400 mPa∙s) for topical dermal application.
The physicochemical properties of the ME or MEH formulations
containing 20S-PPD were characterized as presented in Table 3. The mean droplet 
sizes of the 20S-PPD-loaded ME formulations significantly increased as the 
Labrasol-to-Tween 20 ratios increased (P1: 69.1 nm → P2: 79.1 nm → P3: 99.6 
nm). The mean droplet sizes were further increased by the addition of co-
surfactants (Transcutol HP and soy PC) into the P1 formulation and resultant 
increases in oil-to-water ratios (P4: 106 nm; P5: 110 nm). Notably, TEM images 
showed that the droplet sizes of P5 seemed to be comparable to those of P5-H (Fig. 
3). This result is consistent with a previous study which reported no significant 
influence of Carbopol on the size and morphology of ME droplets [6,9]. The 
surface charges of droplets in all the formulations prepared were near neutral 
(Table 3), probably because they consisted of non-ionic surfactants and oil. This 
may reduce the risk of irritations on the skin or GI tract that can occur more often 
in topical or oral administration of charged ME formulations containing ionic 
surfactants [52]. The mean pH values of all the 20S-PPD-loaded ME and MEH 
formulations ranged from 5.33 to 6.91, which are comparable to a pH value of 
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normal human skin (5.5‒6.5) [53]. The viscosities of ME formulations were 
markedly enhanced by the addition of Carbopol 941, which would be more 
appropriate for topical administration [9]. In the long-term stability test, P1 was 
observed to be stable for 7 days but unstable on 14th day and thereafter, while P5
and P5-H were stable through 56 days (Fig. 10 and Table 4). This may be 
attributable to the addition of co-surfactants (Transcutol HP and soy PC) in F5 and 
F5-H, thereby preventing the aggregation or precipitation of poorly soluble 
ingredients such as 20S-PPD.
Owing to a limited availability of human skin and its high variability in 
lipid and protein compositions depending on bodyweights, genders, ages, and diets, 
hairless mouse skin has been widely regarded as a useful alternative to human skin
[39]. Previous studies have demonstrated a good correlation of skin permeation 
profiles between human and hairless mouse skin [40]. Based on these previous 
researches, hairless mice were regarded as a suitable animal model for alternative 
to the human skin in evaluation of deposition and permeation of 20S-PPD into the 
skin. Besides, Strat-M® membrane is a synthetic and non-animal-based model that 
is predictive of diffusion characteristics in human skin [41]. Due to its similarities
as mentioned on the introduction, the membrane has been reported on its good-
correlation of skin permeation profiles with human and animal skins [41,42]. Thus, 
Strat-M® membrane was also used in evaluation of deposition and permeation of 
20S-PPD. Among P1, P2, and P3, the deposited amounts of 20S-PPD in both the 
epidermis/dermis of hairless mouse skin and Strat-M® membrane were the highest 
in P1. Previous studies reported that the skin permeation and deposition of ME or 
MEH systems were enhanced as their droplet sizes decreased [54,55]. Thus, it 
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appeared that the smaller droplet size of P1 than P2 and P3 (Table 3) may be 
responsible for the enhanced deposition of 20S-PPD in the epidermis/dermis of 
hairless mouse skin and Strat-M® membrane (Fig. 4), but further investigation is 
required to understand the exact mechanism(s). Notably, the incorporation of 
Transcutol as a co-surfactant into P1 significantly enhanced the deposited amount 
of 20S-PPD in both the epidermis/dermis of hairless mouse skin and Strat-M®
membrane (P4 in Fig. 5). Moreover, the incorporation of soy PC as an additional 
co-surfactant into P4 further enhanced the deposition 20S-PPD in Strat-M®
membrane (P5 in Fig. 5). Transcutol can act as a skin permeation enhancer by 
interacting with hydrophilic moieties of skin lipids and proteins [56]. Soy-PC, the 
main component of cell membranes, can readily fuse with the stratum corneum and 
increase its fluidity, thereby exerting skin permeation-enhancing effect [47,57]. 
Thus, it is reasonable that the enhancement of skin deposition of 20S-PPD
observed in P4 and P5 may be attributed to the permeation-enhancing activity of 
co-surfactant added. Based on the results shown in Figs. 4 and 5, P5 were selected 
for further studies on the development of MEH formulation. The in vitro deposition 
of 20S-PPD after applying P5-based hydrogels (P5-H) together with suspension 
and oil solution formulations (serving as control groups) containing 20S-PPD
(0.1%, w/w) was evaluated using Strat-M® membrane (Fig. 6). The deposited 
amount of 20S-PPD was significantly higher in P5-H than in the two control 
groups. Notably, as shown in Figs. 5 and 6, the Strat-M® membrane deposition of
20S-PPD in P5-H (157±10 ng/cm2) was significantly lower than that in P5 (266 ± 
31 ng/cm2). Although the exact mechanism is unclear, a viscous gel network could 
have retarded the release of 20S-PPD from P5-H, resulting in the reduced 
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deposition of 20S-PPD. The in vivo skin deposition of 20S-PPD was evaluated 
after the topical administration of suspension, oil solution, and P5-H containing 
20S-PPD (0.1%, w/w) at a dose of 25 mg/kg to hairless mice (Fig. 7). At all the 
time points studied, the extents of in vivo epidermal/dermal 20S-PPD deposition 
were in the following order: suspension < oil solution < P5-H, which presented a 
similar tendency to the in vitro 20S-PPD deposition in Strat-M® membrane (Fig. 6). 
Recently, it was demonstrated that 20S-PPD showed its anti-wrinkle and 
skin-whitening effects at a concentration range from 250 nM to 1000 nM [38]. 
Assuming that the thickness of epidermis/dermis layer of male hairless mouse skin 
is 510 μm [58], the epidermal/dermal concentrations of 20S-PPD can be calculated 
from its in vivo deposited amounts. As a result, the calculated epidermal/dermal 
concentration values at all the time points were as follows: 200‒274 nM in 
suspension group, 663‒2180 nM in oil solution group, and 1490‒3670 nM in P5-H 
group. In general, drug permeability in human skin tends to be lower by several 
folds than that in mouse skin [39]. Thus, it can be supposed that the suspension and 
oil solution formulations cannot provide a sufficient epidermal/dermal 20S-PPD
concentration level after the topical application, which emphasizes potential merits 
of the MEH formulation (P5-H) developed in this study. Furthermore, the plasma 
concentration of 20S-PPD after the topical administration of P5-H were negligibly 
low and comparable to those of the control (oil solution) group (Fig. 8), indicating 
that our newly-developed MEH formulation (P5-H) does not affect the systemic 
absorption of 20S-PPD administered topically.
In the present study, Strat-M® membrane, as well as hairless mouse skin, 
was used in in vitro deposition studies of 20S-PPD. However, to our best 
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knowledge, little information is available regarding the correlation of skin 
deposition profiles of drugs between Strat-M membrane and hairless mouse skin. 
As shown in Fig. 9, good linear correlations (correlation coefficient r2 = 
0.929‒0.947) between in vitro 20S-PPD deposition in Strat-M membrane and both 
in vitro/in vivo 20S-PPD deposition in hairless mice were found by linear 
regression analysis of skin deposition data for all the formulations studied. Notably,
the slopes of all linear regression was higher than 1.0 (1.73 to 4.37, Fig. 9), which 
means the deposition of 20S-PPD into the Strat-M® membrane was higher than that 
in the epidermis/dermis of hairless mouse skin. It may be attributed to the relatively 
thin thickness (300 μm) of Strat-M® membrane compared to that of hairless mouse
skin (> 500 μm) [41,58]. 
5. Conclusion
In the present study, the Carbopol-based MEH formulations were 
prepared for the topical delivery of a potential skin anti-aging agent, 20S-PPD. The 
formulations successfully enhanced the solubility, long-term stability, in vitro/in 
vivo skin deposition of 20S-PPD with no influence on its systemic absorption in 
mice. Notably, it was found that Strat-M® membrane provided skin deposition data 
well-correlated to those obtained from the present in vitro/in vivo mouse skin 
studies on the deposition of 20S-PPD. To our best knowledge, our results are the 
first reported data regarding the development of 20S-PPD-loaded ME/MEH 
formulations and their deposition profiles in hairless mouse skin and Strat-M®
membrane. Taken together, the ME-based systems developed in this study could 
serve as a potentially effective topical skin delivery system for poorly soluble 
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ginsenosides including 20S-PPD.
Table 1 Solubility (mg/mL) of 20S-PPD in various vehicles.
Phase Vehicles Solubility
Water DW 36.8 ± 4.83 (ng/mL)
Oil
Capmul MCM EP 10.6 ± 1.44
Lauroglycol CC 6.87 ± 0.380
Labrafac CC 3.80 ± 0.820
Surfactant
LAS a 8.63 ± 1.78
Tween 20 5.37 ± 0.887
Isopropyl myristate 2.53 ± 0.734
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Limonene 1.54 ± 0.258
PEG 400 0.0152 ± 0.00487
a PEG-8 caprylic/capric glycerides.
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Table 2 Weight compositions of ME formulations containing 0.1% (w/w) of 20S-PPD.
Water Oil Surfactant Co-surfactant
DW Capmul MCM EP Labrasol Tween 20 Transcutol Soy PC
F1 47.5 17.5 17.5 17.5
F2 47.5 17.5 23.3 11.7
F3 47.5 17.5 26.2 8.8
F4 42.5 17.5 17.5 17.5 5.0
F5 41.5 17.5 17.5 17.5 5.0 1.0
37
Table 3 Physicochemical properties of 20S-PPD-loaded ME and MEH formulations.
Parameters Droplet size 
(nm)






P1 69.1 ± 2.56 0.331 ± 0.006 - 0.353 ± 0.769 5.33 ± 0.257
10.3 ± 0.211 3.28 ± 0.243
P2 79.7 ± 1.80 0.254 ± 0.030 - 0.590 ± 1.13 5.41 ± 0.181
9.87 ± 0.493 3.79 ± 0.334
P3 99.6 ± 2.18 0.306 ± 0.028 - 0.740 ± 1.05 5.38 ± 0.149
9.33 ± 0.785 3.94 ± 0.159
P4 106 ± 1.10 0.347 ± 0.053 - 0.170 ± 0.452 5.45 ± 0.248
10.4 ± 0.191 3.63 ± 0.478
P5 110 ± 7.47 0.436 ± 0.019 - 1.08 ± 0.217 5.55 ± 0.314
11.2 ± 0.339 3.72 ± 0.562
P5-H - - - 6.91 ± 0.249
29400 ± 882 3.56 ± 0.529
c Polydispersity index.
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Table 4 Contents (% of initial loading dose) of 20S-PPD in the oil solution, P1, P5, and P5-H formulations stored at room temperature (RT) 
or 40°C on 0 (immediately after preparation), 7, 14, 28, and 56 days.
Time
Oil solution P1 P5 P5-H
RT 40°C RT 40°C RT 40°C RT 40°C
0 day
(Initial)
98.4 ± 3.54 99.1 ± 3.26 98.4 ± 1.69 100 ± 4.12 102 ± 1.28 101 ± 0.699 98.1 ± 4.58 99.3 ± 2.39
7 days 96.4 ± 4.28 104 ± 2.52 97.6 ± 3.45 98.2 ± 0.842 100 ± 6.59 101 ± 0.287 105 ± 1.12 104 ± 1.24
14 days 90.1 ± 1.78 92.8 ± 2.19 79.1 ± 1.50 81.0 ± 2.99 92.0 ± 2.10 91.8 ± 3.92 96.3 ± 4.20 94.9 ± 2.26
28 days 94.8 ± 2.09 92.1 ± 1.99 74.0 ± 0.764 76.4 ± 2.76 94.8 ± 3.14 95.6 ± 2.18 98.4 ± 1.59 101 ± 3.45
56 days 95.6 ± 3.10 94.1 ± 4.18 67.1 ± 2.84 68.5 ± 3.89 95.1 ± 4.15 94.8 ± 3.39 97.6 ± 3.48 97.7 ± 2.49
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Figure 1 Chemical structure of 20(S)-protopanaxadiol (20S-PPD).
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Figure 2 Pseudo-ternary phase diagrams of water, Capmul MCM EP (oil), and 
surfactant mixture (Smix). The Smix was the mixture of Labrasol and Tween 20 
at 1:1, 2:1, and 3:1 ratio (w/w). Transparent MEs were formed in the clear 
region, and the other region represents turbid emulsions. The closed circle 
represents the compositions of ME formulations prepared with the three 






Figure 3 TEM images and particle size distribution of 20S-PPD-loaded ME 
and MEH formulations. The scale bars represent 0.5 μm.
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Figure 4 In vitro deposition of 20S-PPD in the stratum corneum (SC) and 
epidermis/dermis of hairless mouse skin at 6 hr and that in Strat-M® membrane 
at 3 hr after the topical administration of P1, P2, and P3 at the concentration of 
0.1% (w/w). The rectangular bars and their error bars represent the means and 
standard deviations, respectively (n = 3). The asterisk represents a value 
significantly different from that of the other groups, and the pound sign 
represents a significant difference between the two groups indicated (p < 0.05).
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Figure 5 In vitro skin deposition of 20S-PPD in the stratum corneum (SC) and 
epidermis/dermis of hairless mouse skin at 6 hr and in Strat-M® membrane at 3 
hr after the topical administration of P1, P4, and P5 at the concentration of 
0.1% (w/w). The rectangular bars and their error bars represent the means and 
standard deviations, respectively (n = 3). The asterisk represents a value 
significantly different from that of the other groups, and the pound sign 
represents a significant difference between the two groups indicated (p < 0.05).
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Figure 6 In vitro deposition of 20S-PPD in Strat-M® membrane at 3 hr after 
the topical administration of suspension, oil solution, and P5-H at the 20S-
PPD concentration of 0.1% (w/w). The rectangular bars and their error bars 
represent the means and standard deviations, respectively (n = 3). The asterisk 




(A) Stratum corneum (SC)
(B) Epidermis/Dermis
Figure 7 In vivo skin deposition of 20S-20S-PPD at 3, 6, and 12 hr in the 
stratum corneum (A) and epidermis/dermis (B) of hairless mouse skin after the 
topical administration of suspension, oil solution, and P5-H containing 0.1% 
(w/w) 20S-PPD at a dose of 25 mg/kg. The rectangular bars and their error 
bars represent the means and standard deviations, respectively (n = 3). The 
asterisk represents a value significantly different from that of the other groups, 
and the pound sign represents a significant difference between the two groups 
indicated (p < 0.05).
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Figure 8 In vivo plasma concentration levels of 20S-PPD at 3, 6, and 12 hr 
after the topical administration of suspension, oil solution, and P5-H 
containing 0.1% (w/w) 20S-PPD at a dose of 25 mg/kg in hairless mice. The 
rectangular bars and their error bars represent the means and standard 







Figure 9 Correlation of the in vitro deposited 20S-PPD amounts at 3 hr in 
Strat-M® membrane with the in vitro deposited 20S-PPD amounts at 6 hr (A) 
and in vivo deposited 20S-PPD amounts at 3 hr (B), 6 hr (C), and 12 hr (D) in 
the epidermis/dermis of hairless mouse skin. The bullet symbols and their 
error bars represent the means and standard deviations, respectively (n = 3). 
The solid lines represent the fitted linear regression curves. The solid lines 
represent the fitted linear regression curves.
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Figure 10 Particle size distribution of P1 and P5 stored at room temperature (RT) and 40°C for 14, 28, and 56 days.
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Part II. Capmul MCM EP/Solutol HS 15-based 




Water solubility of drug is an important factor for the absorption into the 
gastro-intestinal (GI) tract after oral administration [59]. Although there are 
complicate mechanisms on the oral absorption into GI tract including active 
transporter (i.e. organic cation transporters and organic anion polypeptide 
transporters) and efflux pump (i.e. p-glycoprotein), the passive diffusion through 
the membrane of GI tract is known to be the main absorption mechanism [60]. 
Therefore, poorly water-soluble agents, which can be included in the 
biopharmaceutics classification system (BCS) class II (low solubility, high 
permeability) and IV (low solubility, low permeability), could have low 
bioavailability because of their low absorption into GI tract [61,62]. Also, low 
solubility can cause large fluctuations on the absorbed into GI tract followed by 
large variation between individuals [63]. Based on the Fick’s laws, low absorption 
into the GI tract by the low aqueous solubility could affect the reduction of 
pharmacological efficacy at an administrated dose [5]. Therefore, solubilization 
techniques are essential for enhancing oral absorption of poorly water-soluble 
compounds and developing clinically- or commercially-useful delivery systems.
Rebamipide (RBP, Fig. 1) has diverse pharmacological activities on the 
stomach such as anti-ulcer, anti-oxidative, and anti-inflammatory effects [64-66]. 
RBP was reported to have anti-ulcer activity by increasing prostaglandin levels as 
increasing the gene expression of cyclooxygenase-2 and decreasing that of 
prostaglandin dehydrogenase in gastric epithelial cells [64]. Previous studies were 
also demonstrated that RBP had anti-oxidative effect by reducing oxygen-derived 
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free radical produced by neutrophils in gastric epithelial cells and blood vessels 
[65]. Besides, RBP inhibited several inflammation mechanisms in the blood 
capillary by prohibiting adhesion of neutrophil to endothelial cells and its 
migration into the tissue [66]. Thus, following the oral dosing of RBP, its systemic 
absorption into the blood circulation or local penetration into the gastric epithelial 
cells is an essential prerequisite for exerting its pharmacological activities. 
However, RBP was classified as a BCS class IV drug which presented a 
low solubility and permeability [67]. Due to its limited aqueous solubility and 
permeability, RBP has a low oral bioavailability of less than 10%, which may 
cause difficulties in optimizing RBP-based therapy [67]. In order to overcome this 
limitation, solid dispersions and nanocrystal formulations were prepared to enhance 
the solubility/dissolution and oral bioavailability of RBP in previous studies 
[68,69]. However, there still exists the necessity of further attempts to develop 
more efficient oral RBP formulations. 
Amongst various drug delivery systems, ME systems has higher drug 
loading capacity by solubilizing water-insoluble drug in the oil phase and can 
present the enhancement of drug permeation into GI tract by the action of Smix
phase [8,11]. For these reasons, ME systems have been reported to significantly 
enhance the solubility/dissolution and oral bioavailability of several BCS class IV 
drugs including docetaxel and cefpodoxime [26,70]. However, to the best of our 
knowledge, there have been few studies on the development of ME systems for the 
enhanced oral absorption of RBP. Therefore, ME systems were studied as drug 
delivery systems for the enhanced oral delivery of RBP in the present study. 
Herein, we report on the development of ME formulations to enhance
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oral delivery of RBP. The RBP-loaded ME formulations were prepared by the 
construction of pseudo ternary phase diagram and characterized in vitro in terms of 
loading capacity, particle-size distribution, morphology, surface charge. The in 
vitro drug release study and in vivo pharmacokinetic study were performed to 
present the enhancement of dissolution and oral bioavailability of RBP compared 
to its suspension. Finally, the in vivo toxicity of RBP-loaded ME after the oral 
administration was also studied. 
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2. Materials and Methods
2.1. Materials
Rebamipide (RBP) was supplied by Hanlim Pharm. Co., Ltd. (Seoul, Korea).
Capmul MCM EP was gifted as a sample from ABITEC Co. (Columbus, OH, 
USA). Lauroglycol CC, Transcutol HP, Capryol 90, and Labrafil WL 2609 BS were 
gifted as samples from Gattefossé Co. (Saint Priest, Cedex, France). Solutol HS 15, 
sodium lauryl sulfate (SLS), and naproxen were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO, USA). Tween 80 was purchased from Tokyo 
Chemical Industry Co., Ltd. (Tokyo, Japan). HPLC grade methanol and acetonitrile 
were purchased from Thermo Fisher Scientific Co. (Pittsburgh, PA, USA). All 
other reagents were of analytical grade. 
2.2. Animal
Male Sprague-Dawley (SD) rats (200-250 g) (Orient Bio, Inc., Seongnam, 
Korea) were used to evaluate in vivo pharmacokinetic profile and intestinal toxicity
of RBP formulatons. They were bred on sawdust and five mice were in each cage. 
They had free access to water and food before the studies. Room illumination was 
on an automatic cycle of 12 hr light/darkness, and room temperature was 
maintained at 25 ± 2°C. They were acclimatized to the presented conditions for at 
least one week prior to the experiments. Experimental protocols for the animals 
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(Approval number: SNU-160311-3-1) used in this study were reviewed by the 
Animal Care and Use Committee of the College of Pharmacy, Seoul National 
University and were in accordance with the National Institutes of Health’s Guide 
for the Care and Use of Laboratory Animals (National Institutes of Health 
Publication Number 85-23, revised 1985).
2.3. Solubility study
The equilibrium solubility of RBP in various vehicles was determined by 
adding excess amount of them into 1 mL of each vehicle. The mixtures containing 
RBP were placed in a shaking incubator (BS-21; Jeio Tech. Co. Ltd., Seoul, Korea) 
with 50 rpm at 37°C for 72 hr. The samples were centrifuged at 16,000 x g for 5 
min and the supernatant was filtrated with 0.20 μm syringe filter to remove the 
excess amount of RBP. Finally, the concentration of RBP in the filtrated solution 
was quantified by HPLC-fluorescence after appropriate dilution with methanol.
2.4. Construction of pseudo-ternary phase diagrams
Based on the solubility test of RBP (Table 1), Capmul MCM EP was 
selected as an oil phase, Solutol HS 15 or Tween 80 were selected as a surfactant, 
and Transcutol or ethanol were selected as a co-surfactant. The pseudo-ternary 
phase diagram studies were performed to find a clear and transparent ME 
formulations. The surfactant and co-surfactant were mixed at different ratios to 
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form the surfactant mixture (Smix). Afterwards, the oil phase and the Smix were 
mixed, where the ratios of oil to Smix were varied as 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 
2:8, and 1:9 (w/w). Then, the water phase (distilled water, DW) was added drop-
wise to each oil and Smix mixture at room temperature with stirring to allow 
equilibration. After equilibrium, the mixtures were visually checked for 
transparency. The points from clear to turbid state were presented on the diagrams.
2.5. Preparation of RBP-loaded MEs
From the clear region of pseudo-ternary phase diagrams, four ME 
formulations (R1‒R4) were selected for further evaluations (Table 2). For the 
preparation of MEs of 0.1% (w/w) RBP, exact amount of RBP was first added into 
Capmul MCM EP and vortex-mixed to dissolve RBP. Then, Smix which was the 
different combination of surfactant and co-surfactant (Solutol HS 15 and ethanol, 
Solutol HS 15 and transcutol, Tween 80 and ethanol, or Tween 80 and transcutol) 
was subsequently added to the oil solution containing RBP under gentle stirring at 
37°C. Afterwards, DW was added dropwise into the above mixture at the same 
condition. 
2.6. Characterization of RBP-loaded MEs
2.6.1. Maximum loading capacity
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To confirm the maximum RBP-loading capacity of ME formulations, 
excess RBP was added into the mixture of oil and Smix, after which the RBP-loaded 
MEs were prepared as the same method before. Then, excess RBP which was not 
included into the droplets of ME was removed by centrifugation for 5.0 min at 
16,000 x g. The supernatant was injected into HPLC-fluorescence for analysis of 
RBP after adequate dilution with methanol.
2.6.2. Particle size and zeta potential
The mean particle size, polydispersity index, intensity distribution of 
particle size, and zeta potential of blank ME and RBP-loaded ME (R1) were 
measured in triplicate by ELS spectrophotometer (ELS 8000, Otsuka Electronics 
Co. Ltd., Tokyo, Japan). The prepared MEs were transferred to a quartz cuvette
before the measurement. All measurements were performed at 25°C in triplicate. 
Besides, in order to estimate the changes in RBP-loaded ME after the oral 
administration, mean droplet size of diluted R1 formulation with pH 1.2 buffer to 
10 and 100-fold was also measured by ELS spectrophotometer.
2.6.3. TEM
The particle morphologies of blank ME and R1 were observed by an 
energy-filtering transmission electron microscopy (TEM) (LIBRA 120, Carl Zeiss, 
Germany) at 80 kV. The samples were placed on a carbon-coated copper grid and 
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negatively stained by 2% phosphotungstic acid followed by drying at room 
temperature before the operations.
2.7. In vitro drug release study
The in vitro drug release study of RBP-loaded ME (R1) in various pH 
buffers compared to its suspension was performed by dialysis method [26]. An 
aliquot (200 µL) of each ME formulation (R1) and suspension in DW containing 
0.1% (w/w) RBP was placed in the dialysis kits (GeBA tubes, molecular weight 
cut-off: 14 KDa; Gene Bio-Application Ltd., Kfar-Hanagid, Israel). Then, the kits 
was immersed in 20 mL of release media (pH 1.2, 4.0, and 6.8 buffer solution 
containing 0.2% SLS (w/v) to maintain sink condition) in a shaking incubator (BS-
21) at 100 rpm at 37°C. At pre-determined time points, a 200-µL aliquot of media 
was collected and replaced with same volume of fresh media. The concentration of 
RBP in samples was determined by using HPLC-fluorescence after appropriate 
dilution with methanol.
2.8. In vivo pharmacokinetic study
Before the experiment, the rats were fasted overnight with access to water. 
The femoral artery of the rats was cannulated with a polyethylene tube (Becton 
Dickinson Diagnostics, Sparks, MD, USA) under anesthesia with Zoletil (20 mg/kg, 
intramuscular injection) (Virbac, Carros, France) [71]. ME formulation (R1) and 
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suspension in DW containing 0.1% (w/w) RBP were directly administered to the 
stomach of rats using an oral sonde at a dose of 5 mg/kg. An approximately 250 µL 
aliquot of blood samples was withdrawn from the femoral artery at pre-determined 
time points (5, 15, 30, 45, 60, 75, 90, 120, 180, 240, and 360 min). The same 
volume of heparinized normal saline (20 IU/mL) was used to flush the cannula 
immediately after each blood sampling to prevent a blood clotting. Plasma samples 
were obtained by centrifugation of the blood samples at 16000 ×g for 5 min and 
stored at ‒20°C until HPLC analysis.
2.9. In vivo intestinal toxicity study
In order to evaluate the intestinal toxicity of RBP formulations, the 
jejunum (approximately 5 cm) of rats was carved out at 24 hr after the oral 
administration of DW, blank ME, RBP suspension, and RBP-loaded ME (R1). The 
segment was washed with PBS and fixed in 4% paraformaldehyde for 24 hr. A 
vertical section of jejunum was stained with hematoxylin-eosin (H&E) and 
observed using an optical microscope (×200). 
2.10. HPLC-fluorescence analysis of RBP
Plasma samples containing RBP were allowed to thaw at room 
temperature for analysis. A 100-µL aliquot of plasma samples was deproteinized 
with a 200-µL aliquot of MeOH containing 10 µg/mL naproxen as an internal 
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standard. After vortex-mixing and centrifugation, a 20-µL aliquot of the 
supernatant was injected into HPLC system. The HPLC system consisted of a 
Waters 2475 Multi λ Fluorescence Detector, e2695 Separations Module, and 
Gemini C18 column (250×4.60 mm, 5 µm; Phenomenex, Torrance, CA, USA). 
The wavelength of the fluorescence detector was set at 320 nm as excitation and 
380 nm as emission. The mobile phase, the mixture of ACN containing 0.1% TEA 
(v/v) and 10 mM KH2PO4 (77:23, v/v), was run at a flow rate of 1 mL/min. The 
calibration standard samples were prepared by spiking working standard into the 
blank plasma, thereby yielding final concentration range of 10.0–1000 ng/mL. The 
response of detector was linear in the concentration range and the mean correlation 
coefficient (r2) for the calibration curve was over 0.999. The signal to noise ratio at
the LLOQ (10.0 ng/mL) was higher than 5.0 and there was no interference from 
any other substances.
.
2.11. Statistical analysis and data analysis
All experiments in this study were performed at least three times, and the 
data are presented as mean ± standard deviation (SD). Statistical analyses were 
carried out using the two-tailed unpaired Student’s t-test and p < 0.05 was 
considered significantly different. Non-compartmental analysis (WinNonlin, 
version 3.1, Pharsight Co., Mountainveiw, CA, USA) was performed to calculate
the following pharmacokinetic parameter: the total area under the plasma 
concentration versus time curve from time zero to last time (360 min) (AUClast). 
The peak plasma concentration (Cmax) and time to reach Cmax (Tmax) were read 
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directly from the experimental data [71].
3. Results
3.1. Preparation of RBP- loaded MEs
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RBP presented a low aqueous solubility in DW (0.01 mg/mL, Table 1). 
Below pH 5.0, its solubility was under 0.037 mg/mL, whereas at pH 7.0 to 8.0, that 
was significantly increased to 2.9 – 4.3 mg/mL (Fig. 2). Due to a low aqueous
solubility of RBP in DW and acidic pH buffer, various oils and surfactants were 
tested to select suitable vehicles for RBP. The rank of the tested compounds in the 
order of decreasing solubility of RBP was as follows: Capmul MCM EP > Capryol 
90 > Labrafil WL 2609 BS > Lauroglycol FCC as oils; Solutol HS 15 > Tween 80
> transcutol > ethanol as surfactants (Table 1). The pseudo-ternary phase diagrams 
consisting of water (DW), oil (Capmul MCM EP), and Smix are shown in Fig. 3. 
The Smix was the mixture of Solutol HS 15 as surfactant and ethanol or transcutol 
as co-surfactant at 3:1 ratio (w/w). Another Smix was the mixture of Tween 80 as 
surfactant and ethanol or transcutol as co-surfactant at 5:3 ratio (w/w). As shown in 
Fig. 3, the formation of clear and transparent MEs was observed in constructing the 
pseudo-ternary phase diagrams with all different Smix combinations. Four different 
ME formulations were selected within the clear and transparent area of MEs 
prepared with the different Smix combinations, i.e. R1, R2, R3, and R4 (Table 2).
3.2. Characterization of RBP-loaded MEs
The compositions of RBP-loaded ME formulations are listed in Table 2. 
Among those MEs (R1 to R4), the maximum loading capacity was highest in R1 
(1.13 mg/mL), followed by R3, R2 and R4. The mean droplet size, polydispersity 
index, and zeta potential of blank ME and RBP-loaded ME (R1) are presented in 
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Table 3. The mean droplet size of both MEs was 86.4 nm, which was not 
significantly different with each other. Moreover, these droplet size were not 
affected by 10 and 100-fold dilution with pH 1.2 buffer. Surface charge of droplets 
was observed to near neutral in both ME formulations. As shown in Fig. 4, 
spherical and nano-sized particles with a narrow size distribution were observed in 
both MEs.
3.3. In vitro release of RBP 
The time profiles of in vitro release of RBP from suspension and RBP-
loaded ME (R1) are shown in Fig. 5. The cumulative release of RBP from 
suspension increased as the pH increased. At pHs 1.2 and 4.0, the extent and rate of 
release of RBP were markedly higher in R1 than suspension (Fig. 5a and 5b). 
However, at pH 6.8, the release rate of RBP was faster in suspension than R1, and 
the cumulative release of RBP was approximately 100% from both groups (Fig. 5c).
3.4. In vivo plasma concentration profiles of RBP after oral 
administration at the dose of 5 mg/kg in rats
The time profiles of in vivo rat plasma concentrations of RBP after the 
oral administration of suspension and RBP-loaded ME (R1) at a dose of 5 mg/kg 
are shown in Fig. 6, and relevant pharmacokinetic parameters are listed in Table 4. 
The Cmax and AUC of RBP were significantly higher in R1 than suspension. The 
Cmax of RBP was enhanced 5.7-fold in R1 as compared with that in suspension 
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(156 ng/mL versus 27.3 ng/mL; p < 0.05). The AUC of RBP in R1 also increased 
4.2-fold compared with that in suspension (31.1 μg·min/mL versus 7.47 
μg·min/mL; p < 0.05). However, the Tmax of RBP was not significantly different 
between both groups. 
3.5. In vivo intestinal toxicity after oral administration at the 
dose of 5 mg/kg in rats
The representative histological sections of jejunum segments at 24 hr 
after oral administration of DW (a), blank ME (b), RBP suspension (c), RBP-
loaded ME (R1, d) to rat were presented on Fig. 7. In all group, any evidence of 
damage to the intestinal jejunum such as fusion of villus and congestion of mucosal 
capillary with blood was not found. Also, there was no distinguishable difference 
among all groups tested. 
4. Discussion
The present study provided novel data on the development of ME 
formulation for the oral delivery of RBP in order to enhance its oral absorption. To 
prepare RBP-loaded ME formulations, Capmul MCM EP was selected as an oil 
phase due to its higher ability to solubilize RBP as compared to the other oils tested 
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(Table 1). Solutol HS 15 and Tween 80 were selected as the surfactant, due to their 
higher ability to solubilize RBP (Table 1). The Smix was the mixture of high HLB 
surfactant (Solutol HS 15, HLB = 16.3; Tween 80, HLB = 15.0) and low HLB co-
surfactant (Transcutol, HLB = 4.2) or ethanol in order to render ME systems to be 
more stable [8,45]. Moreover, ethanol can reduce the interfacial tension and 
improve the flexibility and stability of ME [72]. Based on the rule of high water
portion and low oil/Smix portion, as mentioned above, the RBP-loaded MEs (R1 to 
R4) were selected within the transparent ME area. Among those MEs, the 
maximum loading capacity was highest in R1 (1.13 mg/mL), which was markedly 
higher in comparison with the aqueous solubility of RBP in DW and acidic pH 
buffer (0.01 mg/mL in DW and 0.04 mg/mL in pH 5.0 buffer; Table 1 and Fig. 2). 
Thus, R1 was selected for further studies, and the loading content of RBP in R1 
was set as 0.1% (w/w) in order to prevent aggregation and precipitation in ME 
system.
The physicochemical properties of the ME formulations containing RBP
were characterized as presented in Table 3. The mean droplet size of RBP-loaded 
ME (R1) was not significantly different with that of blank ME (86.4 nm; Table 3), 
probably because RBP was fully-incorporated with in the droplets of ME, not 
dispersed in the water phase. Moreover, the change of mean droplet sizes of R1 
after 10 and 100-fold dilution with pH 1.2 buffer was not significant (75.3 and 85.1 
nm, respectively). Thus, it was expected that the prepared R1 would be stable in the 
gastric fluid after the oral administration. Also, the surface charges of droplets in 
blank ME and R1 prepared were near neutral (Table 3), probably because they 
consisted of non-ionic surfactants and oil. This may reduce the risk of irritations on 
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the GI tract, as mentioned above [52].
In vitro drug release profiles of RBP formulations were evaluated using 
the dialysis method (Fig. 5). Compared with RBP suspension, higher and faster 
release of RBP was observed in RBP-loaded ME (R1) at pH 1.2 and 4.0. It might 
be probably due to the solubility enhancing effect of the ME tested. However, at 
pH 6.8, where RBP can be freely soluble (3.3 mg/mL at pH 7.0; Fig. 2), the rate of 
RBP release was faster in suspension than in R1, while its extent was similar with 
both groups to almost 100%. This result may be attributed to the slow diffusion of 
RBP from the oil phase of ME formulation and the slow penetration process of 
RBP through the dialysis membrane due to the relatively high viscosity of R1 
compared to suspension [43]. 
The in vivo oral pharmacokinetics of RBP formulations was evaluated 
using the rat model (Fig. 6), based on a good correlation regarding the absorption 
after oral administration between in rats and in humans [73]. In the in vivo rat 
pharmacokinetic study, the dose of RBP was set as 5 mg/kg. Oral administration of 
RBP at a dose of 5-10 mg/kg was used in several previous studies for the oral 
delivery of RBP [67-69]. After the oral administration of RBP formulations, 
systemic RBP exposures were significantly higher in RBP-loaded ME (R1) 
compared to suspension group, which is consistent with the in vitro drug release 
study. This improvement of RBP absorption may be attributed to the enhancement
of its solubility and dissolution. Also, permeation-enhancing effects by the 
ingredients of ME could contribute to the improvement of RBP absorption [43]. It 
has been reported that Capmul MCM EP (medium chain mono- and di-glyceride) 
can acts as a membrane permeation enhancer [43,74]. Moreover, Solutol HS 15 has 
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been reported to enhance transepithelial permeability [75]. The intestinal toxicity 
of RBP formulations in rats was evaluated by histological H&E staining (Fig. 7). 
As shown in Fig. 7, no significant intestinal toxicity of RBP-loaded ME (R1) was 
observed compared with DW, RBP suspension, and blank ME. Thus, this result of 
in vivo intestinal toxicity study suggest that RBP-loaded ME formulation prepared 
in this study indicates a potentially safe oral delivery system for RBP.
5. Conclusion
In the present study, ME systems for enhancing the oral absorption of 
RBP were developed and evaluated via in vitro and in vivo studies. The ME 
formulation consisting of Capmul MCM, Solutol HS 15, and ethanol was prepared 
for the oral delivery of RBP based on the construction of pseudo-ternary phase 
diagram. The RBP-loaded ME had spherical nano-sized droplets with narrow size 
distribution and neutral zeta potential. Moreover, the prepared ME significantly 
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enhanced the dissolution and oral bioavailability of RBP with no discernible 
intestinal toxicity. Taken together, the ME systems developed in this study could 
serve as a potentially effective and safe oral delivery system for poorly soluble 
drugs including RBP.
Table 1 Solubility of RBP in various vehicles. 
Type of phase Vehicle Solubility (mg/mL)
Water Distilled water (DW) 0.01 ± 0.00
Oil
Capmul MCM EP 1.73 ± 0.39
Capryol 90 0.17 ± 0.01
Labrafil WL 2609 BS 0.10 ± 0.00
Lauroglycol  FCC 0.04 ± 0.00
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Surfactant
Solutol HS 15 5.60 ± 0.04
Tween 80 1.70 ± 0.02
Transcutol 1.37 ± 0.40
Ethanol 0.82 ± 0.01
Table 2 Weight compositions of ME formulations containing 0.1% (w/w) of 
RBP.



















R3 DW Capmul Tween 80 Ethanol
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Particle size (nm) 86.4 ± 0.3 86.4 ± 1.8
Polydispersity index 0.274 ± 0.004 0.265 ± 0.006
Zeta potential (mV) 0.5 ± 0.1 0.8 ± 0.8
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Table 4 Pharmacokinetic parameters of RBP after the oral administration of 




(ng/mL) 27.3 ± 6.01 156 ± 40.6*
T
max






7.5 ± 1.8 31.1 ± 13.6*
* Significantly different from the other groups (p < 0.05).
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Figure 2 The solubility of RBP at various pH conditions.
74
Smix (Solutol HS 15 : Ethanol = 3:1)




























Smix (Solutol HS 15 : Transcutol = 3:1)




























Smix (Tween 80 : Ethanol = 5:3)
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Figure 3 Pseudo-ternary phase diagrams of systems containing water, Capmul 
MCM EP (oil), and surfactant mixture (Smix). The Smix was the blend of Solutol 
HS 15 as surfactant and ethanol (a) or transcutol (b) as co-surfactant at 3:1 
ratio (w/w). Another Smix was the blend of Tween 80 as surfactant and ethanol 
(c) or transcutol (d) as co-surfactant at 5:3 ratio (w/w). Clear and transparent 
MEs were formed in the ME area, and other area represents turbid emulsion. 




Figure 4 Intensity distribution diagrams of mean diameters and TEM images 
of RBP formulation (a, blank R1; b, RBP-loaded R1). The scale bars represent 
1 μm.
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Figure 5 Time profiles of in vitro drug release of RBP from suspension (), R1 () in pH 1.2 buffer (a), pH 4.0 buffer (b), and pH 6.8 
buffer (c) containing 0.2% SLS (Mean ± SD). 
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Figure 6 Time profiles of arterial plasma concentrations of RBP after oral 
administration of RBP suspension (), R1 () at a dose of 5 mg/kg to rats




Figure 7 Representative histological sections of jejunal segments at 24 hr after 
oral administration of DW (a), blank R1 (b), RBP suspension (c), and R1 (d) to 
rats. The scale bars represent 500 µm.
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국문초록
Application of microemulsion for enhancing topical 
skin absorption of 20(S)-protopanaxadiol and oral 
90
absorption of rebamipide
20(S)-protopanaxadiol (20S-PPD)는 컴파운드 K와 진센노사
이드 Rb1 같은 진센노사이드의 당이 떨어진 대사체로서, 강한 피
부노화방지 작용을 가진다. 그러나, 20S-PPD의 낮은 수상 용해
도와 큰 분자크기 때문에, 이것의 용해도와 피부 투과도를 증진시
켜 피부 흡수를 향상시키기 위해서는 적절한 제형화 전략이 필수
적이다. Rebamipide (RBP)는 강한 항궤양과 항산화 물질이지만, 
BCS class IV에 속하는 약물로서, 10%도 안 되는 낮은 경구 생체
이용률을 가진다. 그러기에, 경구 적용 후 RBP의 약물학적인 작용
이 나타나기 위해서는 RBP의 혈관 순환으로의 전신흡수가 우선적
으로 선행되어야 한다. 따라서, 본 연구에서는 20S-PPD의 국소
피부전달과 RBP의 경구전달을 위해서 마이크로에멀젼 기반의 시
스템을 개발하고자 하였다. 20S-PPD가 함유된 마이크로에멀젼
및 이를 기반으로 한 하이드로겔 제형들을 만들었으며, 그들의 입
자크기 분포, 형태, 최대 로딩 능력, 점도와 pH를 평가하였다. 또
한, 헤어리스 마우스 피부 모델과 인공 피부 모델인 스트라트-엠
멤브레인을 이용하여, 최적화된 마이크로에멀젼 기반의 하이드로
겔 제형에서의 20S-PPD의 인비트로와 인비보 피부 내 잔류 및
투과 양상을 평가하였다. 20S-PPD를 함유한, 카보폴 중심의 마
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이크로에멀젼 기반의 하이드로겔 시스템은 110 nm의 평균 입자
크기와 0.436의 입자크기 분포 지수를 가지며, 성공적으로 만들어
졌다. 해당 제형은 최소 56일 동안 안정하였으며, 이것의 점도는
국소 피부로 적용하기에 충분히 높았다. 해당 제형은 헤어리스 마
우스 모델에서 20S-PPD의 전신흡수에는 영향을 미치지 않으면
서, 20S-PPD의 인비트로 및 인비보 피부 내 잔류를 통계학적으
로 유의하게 증가시켰다. 특히, 20S-PPD의 스트라트-엠 멤브레
인과 인비트로 및 인비보 헤어리스 마우스 피부 내 잔류 결과에
있어서 시험했던 제형들의 순위가 같았다 (상응계수 r2 = 0.929-
0.947). RBP를 함유한 마이크로에멀젼의 경우, 최대 로딩 능력, 
입자크기 분포 및 형태 같은 물성 평가와 인비트로 약물 방출 시
험, 인비보 약물동력학 평가 및 소장 독성 시험을 평가하였다.
RBP를 함유한, Capmul MCM EP 및 Solutol HS 15 기반의 마이
크로에멀젼 시스템은 0.265의 입자크기 분포 지수와 중성의 표면
전하를 가지는 구형의 나노입자(86 nm) 로 이루어졌다. 또한, 해
당 마이크로에멀젼은 구별할 만한 소장 독성을 보이지 않은 체로
RBP의 용출과 경구 생체이용률을 통계학적으로 유의하게 증가시
켰다. 이들을 종합해보면, 이번 연구에서의 마이크로에멀젼 기반의
제형들은 20S-PPD와 RBP를 포함하는 난용성 물질의 흡수를 증
가시키기 위한 효과적인 국소 피부 및 경구 전달 시스템으로서 적
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용할 수 있을 것으로 기대되었다.
주요어: 20(S)-protopanaxadiol (20S-PPD); rebamipide (RBP);
microemulsion (ME)-based systems; topical skin delivery; oral 
delivery; poorly soluble compound
학번: 2011-21702
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